Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Mem. Inst. Oswaldo Cruz ; 110(4): 543-550, 09/06/2015. tab, graf
Artículo en Inglés | LILACS | ID: lil-748862

RESUMEN

The recommended treatment for latent tuberculosis (TB) infection in adults is a daily dose of isoniazid (INH) 300 mg for six months. In Brazil, INH was formulated as 100 mg tablets. The treatment duration and the high pill burden compromised patient adherence to the treatment. The Brazilian National Programme for Tuberculosis requested a new 300 mg INH formulation. The aim of our study was to compare the bioavailability of the new INH 300 mg formulation and three 100 mg tablets of the reference formulation. We conducted a randomised, single dose, open label, two-phase crossover bioequivalence study in 28 healthy human volunteers. The 90% confidence interval for the INH maximum concentration of drug observed in plasma and area under the plasma concentration vs. time curve from time zero to the last measurable concentration “time t” was 89.61-115.92 and 94.82-119.44, respectively. The main limitation of our study was that neither adherence nor the safety profile of multiple doses was evaluated. To determine the level of INH in human plasma, we developed and validated a sensitive, simple and rapid high-performance liquid chromatography-tandem mass spectrometry method. Our results showed that the new formulation was bioequivalent to the 100 mg reference product. This finding supports the use of a single 300 mg tablet daily strategy to treat latent TB. This new formulation may increase patients’ adherence to the treatment and quality of life.


Asunto(s)
Adolescente , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Antituberculosos/farmacocinética , Isoniazida/farmacocinética , Tuberculosis Latente/tratamiento farmacológico , Área Bajo la Curva , Antituberculosos/administración & dosificación , Disponibilidad Biológica , Cromatografía Líquida de Alta Presión , Estudios Cruzados , Isoniazida/administración & dosificación , Tuberculosis Latente/metabolismo , Comprimidos , Espectrometría de Masas en Tándem , Equivalencia Terapéutica
2.
Rev. Soc. Bras. Med. Trop ; 47(6): 756-762, Nov-Dec/2014. tab, graf
Artículo en Inglés | LILACS | ID: lil-732985

RESUMEN

Introduction Parenteral antimony-based compounds are still the standard of care for cutaneous leishmaniasis (CL) treatment in many countries, despite their high toxicity. Previous studies showed that oral azithromycin could be an option for CL treatment. The aim of this study was to evaluate efficacy and safety of oral azithromycin (AZ) for CL treatment compared with injectable meglumine antimoniate (MA). Methods This was a randomized, open-label, 2-arm, non-inferiority clinical trial. Treatment-naïve patients with localized CL were treated with MA (15mg/kg/day up to 1,215mg) or AZ (500mg/day) during 20 consecutive days. The primary efficacy end point was a CL cure 90 days after treatment completion. The analysis was performed with intention-to-treat (ITT) and per protocol (PP) analyses. After an anticipated interim analysis, the study was interrupted due to the high failure rate in the azithromycin group. Results Twenty-four volunteers were included in each group. The MA group had a higher cure rate than the AZ group with the ITT and PP analyses, which were 54.2% versus 20.8% [relative risk (RR) 1.97; 95% confidence intervals (95%CI) 1.13-3.42] and 72.2% versus 23.8% (RR 3.03; 95%CI 1.34-6.87), respectively. No unexpected adverse events were observed. Conclusions ...


Asunto(s)
Adolescente , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Antibacterianos/administración & dosificación , Antiprotozoarios/administración & dosificación , Azitromicina/administración & dosificación , Terminación Anticipada de los Ensayos Clínicos , Leishmaniasis Cutánea/tratamiento farmacológico , Meglumina/administración & dosificación , Compuestos Organometálicos/administración & dosificación , Administración Oral , Brasil , Factores de Tiempo , Insuficiencia del Tratamiento
3.
Rio de Janeiro; Farmaguinhos; 2005. 302 p. tab, graf.
Monografía en Portugués | LILACS | ID: lil-411483
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA